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T-regulator cells or myeloid-derived suppressor cells, and 
overexpression of certain ligands (e.g., programmed death 
ligand-1 [PDL-1]) that inhibit the host’s existing antitumor 
immunity. The latter effect is thought to take place by the 
cancer cells’ overexpressing ligands that can bind inhibitory 
co-receptors expressed by T lymphocytes (also known as 
“immune checkpoints”). Recent advances in melanoma 
research have led to the development of immunotherapies 
that have substantial antitumor effects in other types of 
cancer as well, including lymphoma, renal cell carcinoma, 
and non-small lung cancer (NSCLC). These advances have 
been paradigm-shifting for several reasons. For example, the 
observed immune response patterns have led to marked deep 
tumor regression that often outlasted the period of study. 
Such responses are unprecedented for disease that has been 
refractory to other types of treatment. Second, these new 
forms of immunotherapy have shown activity in tumors 
traditionally viewed as unresponsive to immune therapies, 
raising hopes that any type of cancer might be “targetable” 
by immunotherapies if the right agent can be found. This 
antitumor activity has been most impressive in NSCLC, 
particularly among patients with unresectable disease 
treated with primary radiation therapy, a modality known to 
stimulate antigen production. It is conceivable that 
treatment such as this acts as a type of “in situ vaccine” to 
prime the immune response. Nascent preclinical and early 
clinical findings have supported this possibility, suggesting 
that radiation, through its immune-stimulating properties, 
may eventually be useful as a form of systemic therapy in 
addition to a means of local tumor control. 
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Purpose: Prompt Gamma-ray Timing (PGT) is a method for 
range verification in hadron therapy which requires only 
minor or no interference with clinical routine due to a 
very low hardware footprint. The principal feasibility 
of the method for range verification has already been 
shown in theoretical considerations [1] and in proof-of-
pricipal experiments [2]. Further considerations of the 
clinical feasibility show that a high-throughput data 
acquisition system is crucial [3]. In this work, PGT 
measurements during phantom irradiation with clinical 
beam currents – both during pencil beam scanning (PBS) 
and passive beam formation (double scattering, DS) are 
presented. 
Materials and Methods: By exploiting the time structure of 
the beam on the nanosecond scale, it is possible to 
measure the duration of the emission of secondary photons. 
This duration is linked with the transit time of the 
projectiles in the target. Longer transit times reflect a 
larger range. Since no direct start signal is available, a 
classical time-of-flight measurement against the 
accelerator RF is used. Experiments were conducted at the 
University Proton Therapy Dresden (UPTD) center where 
an IBA Cyclone 230 isochronous cyclotron is installed 
with a fixed RF frequency of 106 MHz. For actual 
clinical application, it is required that the bunch width 
and phase remain constant or are monitored. The shown 
data do not incorporate any kind of bunch timing 
correction and the conditions are assumed to be 
constant. 
As a photon detector, a CeBr3  crystal in the extends of 
ø2”×1” coupled to a PMT is used. It is either read out 
with a CAEN DT5730 waveform digitizer or with a Target 
Systemelektronik U100 dedicated system which is also a 
sampling ADC based readout module. Online pulse processing 
algorithms are applied in both cases to achieve a high 
throughput rate. The ADCs were synchronized to the RF. 
Experiments during DS were conducted parasitically 
during the workflow training with an anthropomorphic 
phantom. For the PBS measurements dedicated beam time 
could be scheduled at the therapeutic treatment room. 
A rectangular dose distribution was impinged on a 
homogeneous PMMA target. In DS mode, a lead shielding 
was placed between the detector and the nozzle in 
order to reduce background radiation which originates 
from the nozzle. 
Results: In both cases, it was possible to identify the 
individual phases of beam delivery. In DS mode, the 
periodic modulation at 600 Hz which is synchronized with 
the beam formation equipment can be seen. In PBS, 
single layers and single spots can be recognized 
(figure 1). After data selection, the beam microstructure is 
revealed in PBS as well as in DS mode although it is 
considerably less clear in the DS case. 
Conclusions: The experimental techniques which are 
required for a clinical implementation of PGT are being 
evaluated under clinical beam conditions. The beam 
delivery mode has major impact on the data quality. 
 
 
 
 
 
 
 
Figure 1: Count rate over time during DS (left) and PBS 
(right), recorded at 2 Gy/min at different distances. 
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Purpose: At the OncoRay center in Dresden at proton 
therapy facility is in operation. The first patient was 
treated in December 2014. The system is driven by an 
IBA (IBA Proton Therapy, Louvain-la-Neuve, Belgium) 
Cyclone 230 isochronous cyclotron with a maximum 
proton energy of 230 MeV. Patients are treated in one 
room equipped with a 360° rotating gantry. Besides 
patient treatment a strong focus is on research. A 
dedicated experimental room is part of the facility. In the 
current state of expansion this room is equipped with a 
fixed beam line. Beam energies between 70 and 230 MeV 
and currents up to about 120 nA at 230 MeV can be 
provided. 
Materials and Methods: An in house developed control 
system (figure 1) allows for a parallel operation of the 
treatment and the experimental beamline. Absolute 
priority for the treatment room is ensured by the control 
software. 
The beam current is controlled by a dedicated 
hardware directly. Continuous wave beams as well as 
pulsed beams with repetition rates up to 333 Hz with 
variable duty cycles are available. The beam is 
monitored by means of a segmented ionization 
chamber. The beam can be activated manually, for a 
defined time or until a certain charge has been reached 
at the beam exit. A direct continuance after a beam switch 
to the treatment room is possible. 
Results: The proton therapy system itself is operated by 
an IBA team, that ensures excellent beam stability and 
availability. Since only one treatment room is present, 
experiments can be performed conveniently during the day 
shifts. Requests from the treatment room cause 
interruptions of 1-2 min duration in intervals of about 20 
min. 
Conclusions: In summary, the OncoRay center is equipped 
with an experimental beamline that combines the 
reliability and beam quality of a commercial clinical proton 
therapy system with the flexibility of an in house 
developed control system whose design parameters are 
governed by the needs of physical and translational 
research. 
 
 
Figure 1: A screenshot of the interface for the operator at 
the control room for the experimental area. 
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Purpose: Radiation therapy is currently prescribed to more 
than 60 % of cancer patients1. However, effective treatment 
is often limited by tumor visualization and collateral damage 
of healthy tissues. One possibility to overcome this problem, 
besides using a local approach such as stereotactic 
radiosurgery, is combining radiation with nanoparticles 
containing high-Z elements which are known to boost locally 
the efficacy of radiation exposure during cancer therapy. In 
this context, we developed gadolinium-based nanoparticles 
named AGuIX (Activation-Guided Irradiation by X-ray) for 
MRI-guided radiotherapy. 
Material and methods: (AGuIX) nanoparticles were obtained 
as previously described2. We performed in vitro 
radiosensitization clonogenic assay with 220kVp X-ray at 
doses ranging from 0 to 6 Gy on B16F10 mouse melanoma cell 
line, in addition to cell uptake characterization using TEM 
and confocal microscopy. In vivo, B16F10 mouse melanoma 
cells were orthotopically grafted into mouse brains to mimic 
human melanoma brain metastases. After intravenous 
injection of 10 µmol of (AGuIX) into mice bearing B16F10, MR 
and intravital two photon microscopy imaging were 
performed to determine the maximum tumor uptake, and 
tumor vs. healthy tissue ratio before radiation therapy. 
Similar to the clinical workflow, an image guided cone-beam 
CT (CBCT) was performed prior to irradiation exposure to 
calculate the delivered dose during whole brain radiotherapy 
(WBRT) to the brain, the metastases and other organs at risk. 
Results: Radiosensitization shows a significant effect (P<0.05) 
when the (AGuIX) are combined with 220 kVp X-rays exposure 
in vitro. The percentage enhancement factor at 2 Gy (%EF 2 
Gy) was 60 % compared with that for radiation alone, with a 
significant increase in DNA double strand breaks (P<0.01). In 
vivo the (AGuIX) nanoparticles accumulate passively in brain 
tumors; such phenomenon has previously been reported in 
brain-tumor bearing animals3. After radiation exposure, the 
increase in life spans (ILS) compared to control group was 
8.3% for the animals that were only irradiated and increased 
to 25% with pre-injection of (AGuIX) nanoparticles; such 
increase corresponds to 15.4% compared to irradiated 
animals (P=0.0025). Histological observation of the brains 
indicated the presence of large metastases for the control 
and irradiated only group compared to the group treated by 
the combination of irradiation with nanoparticles4,5.  
Conclusion: (AGuIX) nanoparticles are not only potential 
radiosensitizing agent, but it also acts as positive contrast 
agent for MRI, which allows accurate delineation of the 
tumor region instead of using conventional CT. Regulatory 
toxicity investigations demonstrated the absence of any side 
effects, even at repeated injections. A clinical trial phase I 
on patients with multiple brain metastases will be launched 
in France winter 2016. 
                      
 
Fig. 1. Guided and enhanced radiotherapy with (AGuIX) 
nanoparticles. 
